Every milligram of zinc you absorb from food passes through a single gateway in the intestinal wall: a protein called ZIP4¹¹ ZIP4
Zinc-Iron transporter Protein 4, encoded by SLC39A4 on chromosome 8q24.3; expressed at the apical membrane of duodenal and jejunal enterocytes; the sole high-capacity zinc importer in the mammalian gut. When ZIP4 stops working entirely — through rare pathogenic mutations — the result is acrodermatitis enteropathica, a severe inherited zinc deficiency disease. But rs1871534 is not one of those rare mutations. It is one of the most common SNPs in the human genome, and its story is one of the most striking examples of recent positive selection in human evolution.

The rs1871534 variant swaps a leucine for a valine at position 372 of the ZIP4 protein (Leu372Val). The valine form — the C allele on the plus strand — is carried by essentially every person of West African descent and by virtually nobody of European or East Asian ancestry. The [FST | a measure of population differentiation ranging from 0 (identical frequency) to 1 (completely different); values above 0.90 are extremely rare for common SNPs] between Europeans and Yorubans (West Africans) for this variant is 0.99999977 — the most differentiated common SNP in the genome at the time of its discovery.

The Mechanism

Engelken et al. (2014)²² Engelken et al. (2014) investigated why this SNP shows such extreme population differentiation. They expressed both the Leu372 and Val372 forms of ZIP4 in HeLa cells and measured three outcomes: protein levels at the cell surface, baseline intracellular zinc, and zinc uptake rate. Val372 (the West African form) showed significantly reduced surface expression, lower basal intracellular zinc, and reduced zinc uptake compared to Leu372. The variant does not eliminate ZIP4 function — it reduces its efficiency.

ZIP4 is regulated through zinc-dependent endocytosis: when zinc is abundant, ZIP4 is pulled off the cell surface and degraded; when zinc is scarce, ZIP4 is rapidly trafficked back to the apical membrane to capture more zinc. The Leu372Val substitution sits in a transmembrane domain of the protein and appears to alter the protein's stability at the cell surface — [effectively reducing the maximum capacity of the intestinal zinc absorption system | Wang et al. 2004 showed that reduced surface expression is the primary mechanism by which ZIP4 missense variants impair transport (PMID 14709598)].

The Evidence

The key study is the 2014 analysis by Engelken and colleagues³³ Engelken and colleagues
Engelken J et al. Extreme population differences in the human zinc transporter ZIP4 (SLC39A4) are explained by positive selection in Sub-Saharan Africa. PLoS Genet, 2014. Using coalescent simulations that accounted for local recombination hotspots, they demonstrated that the extreme allele frequency differences cannot be explained by genetic drift alone — directional selection favoring the Val372 allele in sub-Saharan Africa with a selection coefficient of approximately 0.5% is the most parsimonious explanation. This is a modest but sustained selective advantage, consistent with the allele rising to near-fixation over thousands of generations.

Why would reduced zinc absorption be advantageous? Zinc is essential for many bacterial and parasitic pathogens. The human immune system uses zinc-starvation as a front-line antimicrobial weapon — macrophages deliberately flood zinc into vesicles containing intracellular bacteria to kill them. The authors hypothesize that reduced intestinal zinc uptake by Val372-ZIP4 may also reduce systemic zinc availability to pathogens, conferring a survival advantage in high-pathogen-burden environments like sub-Saharan Africa. This hypothesis remains speculative — no direct in vivo evidence in humans has yet tested it — but it is consistent with the geographic distribution of selection and with what is known about nutritional immunity.

The functional consequence for the individual: Val372/Val372 (CC) homozygotes absorb zinc less efficiently than Leu372/Leu372 (GG) carriers. At typical dietary zinc intakes this may not produce frank deficiency, but it creates a narrower margin — particularly on high-phytate diets that already impair zinc bioavailability.

Practical Actions

For CC carriers (almost exclusively of West African or recent African ancestry), the gap between dietary zinc intake and actual absorption is wider than for GG carriers. Phytate-rich staple diets — common in sub-Saharan Africa — compound this by further reducing bioavailability. The most direct interventions are dietary: prioritise animal-source zinc (which bypasses phytate inhibition) and reduce phytate intake through food preparation techniques. Monitoring serum zinc provides an objective check on zinc adequacy.

For CG heterozygotes, a modest intermediate effect on ZIP4 surface expression is expected; the practical relevance is smaller but the same dietary principles apply.

Interactions

With SLC30A1 (ZnT1, rs3738198): ZIP4 handles zinc import at the apical membrane; ZnT1 handles export at the basolateral membrane. Individuals carrying reduced-function alleles at both transporters face a double constraint on net zinc delivery to the portal circulation.

With dietary phytate: The gene-diet interaction is the dominant modifiable factor. Phytate in legumes, wholegrains, and maize-based staples forms insoluble zinc-phytate complexes in the gut, reducing absorption to 10–15% vs 25–40% for animal-source zinc. For CC carriers, this interaction is clinically meaningful — phytate in the context of reduced ZIP4 capacity compounds into significant functional zinc inadequacy.

With pathogenic SLC39A4 variants: Compound heterozygosity — one Leu372Val allele plus one pathogenic acrodermatitis enteropathica allele on the other chromosome — has not been systematically studied but is theoretically possible. Because the pathogenic variants (p.Arg95Cys, p.Gln278His, etc.) cause null or near-null ZIP4 function, the Leu372Val allele would provide residual function on that chromosome.

The HPS3 gene encodes a subunit of the BLOC-2 complex¹¹ BLOC-2 complex
Biogenesis of Lysosome-related Organelles Complex 2, a multi-protein machine that organizes the intracellular trafficking of cargo into specialized organelles — including platelet dense granules (which store ADP and serotonin needed for blood clotting) and melanosomes (which produce and distribute skin and eye pigment). The rs201227603 variant disrupts a splice donor site at the start of intron 5, causing the cell's RNA-splicing machinery to skip exon 5 entirely and produce a non-functional protein. In people who inherit two copies, this causes Hermansky-Pudlak syndrome type 3 (HPS3)²² Hermansky-Pudlak syndrome type 3 (HPS3), a rare autosomal recessive disorder. In people who carry one copy, there are no symptoms — but the variant can be passed to children.

The Mechanism

rs201227603 lies at position chr3:149,145,547 (GRCh38) within the HPS3 gene on the plus strand. The G→A change at the +1 position of intron 5 destroys the canonical GT splice donor sequence³³ GT splice donor sequence
The GT dinucleotide at the start of almost every intron is essential for the spliceosome to recognize and excise the intron, causing exon 5 skipping and a frameshift that eliminates BLOC-2 function. Without functional BLOC-2, melanosomes fail to mature properly (causing oculocutaneous albinism) and platelet dense granules fail to form (causing a delta storage pool deficiency⁴⁴ delta storage pool deficiency
Platelets normally store ADP, ATP, and serotonin in dense granules; without them, the secondary wave of platelet aggregation fails, prolonging bleeding time). Critically, HPS3 does not affect the BLOC-3 or AP-3 complexes that are responsible for pulmonary fibrosis in HPS types 1, 2, and 4. HPS3 is among the milder HPS subtypes: hypopigmentation can be subtle enough to be missed, and pulmonary fibrosis is not a feature.

The Evidence

Huizing et al. (2001)⁵⁵ Huizing et al. (2001) first characterized the 1303+1G→A mutation (now rs201227603 in dbSNP) as a founder variant in Ashkenazi Jews, identifying five of eight non-Puerto Rican HPS3 patients as being of Ashkenazi descent and finding a carrier frequency of approximately 1 in 235 (0.43%) in anonymous Ashkenazi Jewish samples. Current gnomAD v4 exome data confirms the striking population stratification: the variant reaches an allele frequency of ~0.172% in Ashkenazi Jews, versus <0.001% in all other populations. Two copies would cause full HPS3 disease; in the Ashkenazi Jewish community, the expected disease frequency is approximately 1 in 33,000 births.

Huizing et al. (2020)⁶⁶ Huizing et al. (2020) comprehensively reviewed all 264 variants across 10 HPS genes and confirmed that pulmonary fibrosis is restricted to BLOC-3 (HPS1, HPS4) and AP-3 (HPS2) deficiencies — not to HPS3 (BLOC-2 deficiency) — making prognosis for HPS3 significantly better than for the most severe subtypes.

Marek-Yagel et al. (2022)⁷⁷ Marek-Yagel et al. (2022) described six compound heterozygous HPS3 patients carrying a splice site variant (c.1163+1G>A) and a large deletion; all presented with variable oculocutaneous albinism and ecchymoses, but none had pulmonary involvement, consistent with the mild BLOC-2 phenotype.

Practical Actions

For carriers (one copy): no health effects expected, but genetic counseling is valuable, particularly for Ashkenazi Jewish individuals planning families. If both partners carry the variant, each pregnancy has a 25% chance of producing an affected child.

For homozygous individuals (two copies, causing HPS3 disease): management centers on eye protection (albinism increases UV sensitivity and reduces visual acuity), bleeding precautions (dense granule deficiency prolongs bleeding time), and monitoring skin for UV-induced damage. Desmopressin (DDAVP) can correct the prolonged bleeding time prior to procedures. NSAIDs and aspirin must be strictly avoided, as they further impair platelet function.

Interactions

HPS3 disease requires biallelic loss-of-function in the HPS3 gene. Compound heterozygosity (one splice donor variant + one deletion or other loss-of-function allele) produces the same clinical picture as homozygosity. No published compound action is documented between rs201227603 and variants in other HPS genes, though digenic combinations are theoretically possible in pathway biology.

Fibrinogen is the blood's primary scaffolding protein — the raw material that thrombin converts into fibrin, the structural backbone of every blood clot. But fibrinogen is not a single molecule. The liver produces two principal isoforms that differ at their gamma chain tip: fibrinogen gamma-A¹¹ fibrinogen gamma-A
The predominant isoform (~85-90% of total fibrinogen) with standard interactions with thrombin, platelets, and Factor XIII and fibrinogen gamma-prime²² fibrinogen gamma-prime
A minority isoform (~10-15% of total) with an extended gamma chain that uniquely binds thrombin, Factor XIII, and has distinct platelet interactions. The rs2066865 variant determines how much gamma-prime your liver makes relative to gamma-A — and that ratio turns out to matter for your thrombosis risk.

The Mechanism

The FGG gene on chromosome 4 encodes the fibrinogen gamma chain. Two alternative polyadenylation sites in its 3' downstream region³³ 3' downstream region
The non-coding region after the gene's stop codon that controls mRNA processing and determines which protein isoform is produced create two mRNA transcripts: a shorter one producing the standard gamma-A chain and a longer one producing the extended gamma-prime chain. The rs2066865 variant (10034C>T on the coding strand; G>A on the plus strand) sits in this alternative splicing control region and shifts the balance toward the shorter transcript — meaning carriers of the A allele produce proportionally less fibrinogen gamma-prime and more gamma-A.

Fibrinogen gamma-prime has several unique properties that modulate clot risk. It binds thrombin with high affinity through exosite II, effectively sequestering thrombin and limiting its availability for further coagulation. It also alters clot architecture⁴⁴ clot architecture
Fibrinogen gamma-prime produces clots with a looser, more porous structure that is more easily dissolved by fibrinolysis — the body's clot-clearing system. When gamma-prime levels fall (as in A-allele carriers), clots form more readily and are more resistant to fibrinolysis — a procoagulant shift by two independent mechanisms simultaneously.

The Evidence

The original landmark study by Uitte de Willige et al.⁵⁵ Uitte de Willige et al.
Published in Blood 2005, the first paper to identify rs2066865 as an independent DVT risk factor identified this variant as an independent deep venous thrombosis risk factor through the gamma-prime fibrinogen mechanism. The largest genetic confirmation came from a UK Biobank and Veterans Affairs genome-wide study by Klarin et al.⁶⁶ UK Biobank and Veterans Affairs genome-wide study by Klarin et al.
816,694 participants; p-value 10⁻⁸⁸ for VTE association; OR 1.22 per A allele — one of the strongest genetic signals in the VTE literature with over 800,000 participants, establishing an odds ratio of approximately 1.22 per A allele at genome-wide significance (p = 10⁻⁸⁸).

In a prospective population-based study from Norway⁷⁷ prospective population-based study from Norway
640 VTE cases among 3,734 age-weighted participants in the Tromsø cohort, homozygous AA carriers showed a hazard ratio of 1.7 (95% CI 1.2–2.3) for VTE. When active cancer was present, the risk compounded further to HR 2.0 — synergy between genetic and acquired thrombotic risk.

A large Czech study of 2,630 VTE patients versus 2,637 controls⁸⁸ 2,630 VTE patients versus 2,637 controls
Kvasnicka et al. 2025, Clinical and Applied Thrombosis/Hemostasis confirmed a dose-response relationship: heterozygous GA carriers had 1.37-fold increased VTE risk and homozygous AA carriers had 1.77-fold increased risk. A separate microvascular surgery cohort found microvascular thrombosis rates of 7.6% (GG), 22.7% (GA), and 33% (AA)⁹⁹ microvascular thrombosis rates of 7.6% (GG), 22.7% (GA), and 33% (AA)
Drizlionoka et al. 2019; 104 patients undergoing microvascular flap surgery, with plasma fibrinogen concentrations also rising with each A allele.

The association extends beyond venous thrombosis. In Han Chinese participants¹⁰¹⁰ Han Chinese participants
Discovery and replication cohorts totaling 1,268 PE cases and 17,663 controls, rs2066865 reached genome-wide significance for pulmonary embolism (p = 3.81 × 10⁻¹⁴, OR 1.37). In systemic lupus erythematosus patients, the variant showed OR 1.91 for venous thrombosis in white participants and OR 2.19 for arterial thrombosis in Hispanic Americans — suggesting that the procoagulant phenotype interacts with the inflammatory milieu of autoimmune disease.

Practical Implications

The per-allele OR of ~1.22 translates to a moderate absolute risk increase. Unlike the rare, high-penetrance thrombophilias (Factor V Leiden homozygosity, antithrombin deficiency), rs2066865 is common enough — about 7% of people carry two A alleles — that it contributes meaningfully to population-attributable VTE burden. The effect is additive: each additional A allele incrementally shifts the gamma/gamma-prime ratio and modestly elevates risk.

For carriers, awareness is most actionable before high-risk periods: surgery, prolonged immobilization, long-haul travel, hormonal changes (pregnancy, oral contraceptive initiation), and during cancer treatment. The variant also modifies fibrinogen levels measurably — AA homozygotes in the Drizlionoka cohort had nearly double the plasma fibrinogen of GG homozygotes — which is itself an established cardiovascular risk factor.

Interactions

The most clinically important interactions are with other inherited thrombophilias. Carriers of both rs2066865 A allele(s) and Factor V Leiden (rs6025)¹¹¹¹ Factor V Leiden (rs6025)
F5 R506Q, the most common inherited thrombophilia at 5% carrier frequency in Europeans; creates resistance to activated protein C, a natural anticoagulant or prothrombin G20210A (rs1799963)¹²¹² prothrombin G20210A (rs1799963)
F2 3'UTR variant that elevates prothrombin production by 30%; the second most common inherited thrombophilia face a compounded risk from independent pro-coagulant mechanisms acting simultaneously. Similarly, Factor XI rs2289252¹³¹³ Factor XI rs2289252
F11 intronic variant associated with elevated Factor XI levels and modestly elevated VTE risk is included in clinical thrombophilia panels alongside rs2066865. Acquired thrombophilic states — cancer, antiphospholipid syndrome, pregnancy — add independently to the genetic baseline.

The SLC26A3 gene¹¹ SLC26A3 gene
Solute Carrier Family 26 Member 3, also known as DRA (Down-Regulated in Adenoma) — a chloride/bicarbonate antiporter expressed at the apical membrane of intestinal epithelial cells and goblet cells encodes the intestine's primary chloride-absorbing transporter. By exchanging luminal chloride for intracellular bicarbonate across the apical membrane of colonocytes and goblet cells, SLC26A3 simultaneously drives chloride absorption and maintains the alkaline surface pH that protects the mucus layer, shapes the colonic microbiome, and gates mucosal immune activation. rs2108225 is a regulatory tag SNP²² regulatory tag SNP
A non-coding variant approximately 9 kb downstream of the SLC26A3 transcription end site — identified in a GWAS; likely in LD with a functional variant affecting SLC26A3 expression or regulation in intestinal tissue at the SLC26A3 locus identified in the first large-scale GWAS of ulcerative colitis in a Japanese population.

The Mechanism

SLC26A3/DRA operates as a Cl⁻/HCO₃⁻ antiporter³³ Cl⁻/HCO₃⁻ antiporter
An antiporter moves two ions in opposite directions across the membrane simultaneously; DRA imports Cl⁻ while exporting HCO₃⁻, coupling chloride absorption to bicarbonate secretion on the apical (luminal) surface of intestinal epithelial cells. This exchange serves three interlocking functions: it absorbs chloride from the intestinal lumen (preventing chloride diarrhea), it secretes bicarbonate into the mucus layer (alkalinizing the mucosal surface pH), and — in goblet cells — it drives the bicarbonate-dependent expansion of mucin glycoproteins that form the mucus barrier.

When SLC26A3 activity is reduced, these three processes fail together. Studies in DRA-knockout and TNF-α-overexpressing mouse models⁴⁴ Studies in DRA-knockout and TNF-α-overexpressing mouse models
Xiao et al. used TNF-α-transgenic mice with documented DRA downregulation; DRA null mice show severe chloride diarrhea with absent colonic bicarbonate secretion demonstrate that even mild colonic inflammation is sufficient to severely deplete DRA expression, producing a "strong defect in ileocolonic bicarbonate secretion" independent of changes to other ion transporters (CFTR, NHE3, NBC). The resulting acidified mucus layer creates a hostile environment for protective commensal bacteria that depend on alkaline pH, while favouring acid-tolerant pathobionts. A thinner, less-expanded mucus layer then exposes the epithelium directly to luminal microbial products, triggering pattern-recognition receptor activation and NF-κB-driven cytokine release.

The loop closes via reciprocal TNF-α/DRA regulation⁵⁵ reciprocal TNF-α/DRA regulation
DRA knockdown increases TNF-α secretion from intestinal cells; TNF-α in turn dose-dependently suppresses DRA expression — a bidirectional circuit that can sustain mucosal inflammation once initiated. TNF-α suppresses DRA expression in intestinal epithelial cells, and DRA silencing elevates TNF-α secretion in the same cells. Risk allele carriers at rs2108225 may start with constitutively lower SLC26A3 expression or a steeper inflammatory-suppression response, making it easier for this feedback loop to become self-sustaining.

The Evidence

The primary evidence comes from a two-stage Japanese genome-wide association study⁶⁶ two-stage Japanese genome-wide association study
Asano et al. (2009): Stage 1 — 1,384 UC cases and 3,057 controls on the Illumina Human610-Quad BeadChip; Stage 2 — independent replication cohort by Asano et al. (2009), which genotyped 1,384 Japanese individuals with ulcerative colitis and 3,057 controls across approximately 590,000 SNPs. The SLC26A3 locus reached genome-wide suggestive significance at p = 9.50 × 10⁻⁸ with an odds ratio of 1.32 (95% CI 1.19–1.47) per risk A allele — ranking it alongside FCGR2A and a chromosome 13q12 locus as one of three novel UC susceptibility signals identified in that study.

A Chinese case-control study⁷⁷ Chinese case-control study
Shao et al. (2018) in International Journal of Colorectal Disease: 5 SLC26A3 polymorphisms typed in Chinese UC patients and healthy controls using SNaPshot genotyping; colonic tissue DRA expression assessed by qRT-PCR and immunohistochemistry confirmed that rs2108225 variation in SLC26A3 increases UC risk and is associated with altered DRA mRNA and protein expression in colonic tissue from UC patients, providing functional support for the GWAS finding. The mechanistic studies on DRA downregulation (PMIDs 21557395, 29286110) were conducted in cell and animal systems and are therefore indirect but biologically coherent evidence for the pathway.

The SLC26A3 UC signal has not been consistently replicated in large European IBD GWAS meta-analyses, which may reflect population-specific linkage disequilibrium patterns — the causal variant(s) at the locus may be in strong LD with rs2108225 in East Asian populations but not in Europeans.

Practical Actions

For risk A allele carriers, the actionable implication centres on protecting mucosal bicarbonate secretion and the gut epithelial barrier. Short-chain fatty acids (SCFAs)⁸⁸ Short-chain fatty acids (SCFAs)
Butyrate produced by colonic fermentation of dietary fibre upregulates DRA expression in intestinal epithelial cells via histone deacetylase inhibition, directly increasing SLC26A3 activity — particularly butyrate — directly upregulate DRA expression in colonocytes, offering a dietary lever to compensate for genetically reduced SLC26A3 activity. Fermentable dietary fibre (inulin, resistant starch, pectin) that drives butyrate production by gut bacteria is a concrete, mechanism-specific intervention for this locus.

All-trans retinoic acid (ATRA)⁹⁹ All-trans retinoic acid (ATRA)
The active form of vitamin A; it upregulates DRA by blocking IFN-γ-induced STAT1 phosphorylation, counteracting a key inflammatory suppression pathway for SLC26A3 blocks the IFN-γ/STAT1 pathway that suppresses DRA during inflammation, directly preserving SLC26A3 expression under inflammatory conditions. Adequate vitamin A status supports this ATRA-dependent DRA maintenance pathway.

Interactions

The three UC susceptibility loci identified by Asano et al. (rs2108225 at SLC26A3, rs1801274 at FCGR2A, and rs17085007 at 13q12) represent distinct biological pathways — innate epithelial barrier (SLC26A3), immunoglobulin receptor signalling (FCGR2A), and an unknown locus (13q12). Their combined contribution to UC risk is additive rather than synergistic, and no compound effect has been characterised in published literature.

The IL23R¹¹ IL23R
interleukin-23 receptor gene on chromosome 1p31.3, encoding the specific binding subunit of the IL-23 receptor complex gene encodes one half of the receptor complex that captures interleukin-23 — a cytokine that sits at the top of the Th17 inflammatory cascade. When IL-23 binds to its receptor, it triggers a chain of molecular events that expands and sustains populations of Th17 cells²² Th17 cells
a specialized subset of CD4+ T helper cells that produce IL-17A, IL-17F, and IL-22, driving tissue inflammation in skin, joints, and gut, the immune cells responsible for much of the tissue damage seen in psoriasis, psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease. The rs2201841 variant is an intronic SNP located within an intron of IL23R that has emerged across multiple independent genome-wide association studies as one of the most consistently replicated non-HLA genetic risk factors³³ most consistently replicated non-HLA genetic risk factors
The IL23R locus reached P<5×10−8 in the initial GWAS of psoriasis (Capon et al. 2009) and has been confirmed across Crohn's disease, AS, and psoriatic arthritis GWAS for this cluster of overlapping autoimmune and inflammatory conditions.

The Mechanism

IL23R pairs with IL12RB1/IL-12Rβ1 to form the complete IL-23 receptor complex on the surface of T cells, natural killer cells, innate lymphoid cells, and macrophages. When IL-23 engages this heterodimer, it activates JAK2 and TYK2⁴⁴ JAK2 and TYK2
Janus kinase family members that are constitutively associated with the receptor cytoplasmic domain and initiate downstream signaling upon receptor dimerization, which in turn phosphorylate STAT3. Activated STAT3 translocates to the nucleus and drives expression of RORγt — the master transcription factor for Th17 cell identity — and reinforces expression of IL-17A, IL-17F, IL-22, and additional pro-inflammatory cytokines.

The rs2201841 G allele is intronic and does not change the receptor protein sequence. Its mechanism is likely regulatory⁵⁵ regulatory
intronic variants can affect splicing efficiency, mRNA stability, or transcription factor binding sites within enhancer elements embedded in introns. The most telling evidence that this locus matters is that the known protective missense variant rs11209026 (R381Q)⁶⁶ protective missense variant rs11209026 (R381Q)
A separate IL23R variant — Arg381Gln — directly reduces receptor function and is strongly protective against all the same diseases where rs2201841 G confers risk; the two variants are in partial LD and their effects point in opposite directions in the same gene reduces IL-23 receptor signaling and is strongly protective against psoriasis, Crohn's disease, and AS. Carriers of rs2201841 G who lack the R381Q protective allele have a receptor that is neither hyperactive (no coding change) nor dampened, but the intronic variant may subtly upregulate receptor expression or maintain signaling efficiency in ways that tip inflammatory balance toward Th17 expansion.

The downstream consequences are shared across conditions. In skin, IL-23-stimulated Th17 cells produce IL-17A that drives keratinocyte hyperproliferation and the characteristic plaques of psoriasis. In synovium, IL-17A promotes bone erosion and synovial inflammation in psoriatic arthritis. In the gut, IL-23-driven Th17 responses contribute to the epithelial damage and granulomatous inflammation of Crohn's disease. The genetic architecture⁷⁷ genetic architecture
rs2201841 reaches genome-wide significance across psoriasis, Crohn's disease, and ankylosing spondylitis — the same three conditions for which IL-17 and IL-23 inhibitors are clinically approved of these conditions is closely intertwined, reflecting their shared pathogenic axis.

The Evidence

A meta-analysis of 13 studies examining IL23R polymorphisms in psoriasis and PsA⁸⁸ meta-analysis of 13 studies examining IL23R polymorphisms in psoriasis and PsA
Duan et al., Inflammation Research, 2012 found rs2201841 to be significantly associated with psoriasis across all genotypic models: GG vs. AA (OR 1.34, 95% CI 1.15–1.56), dominant (OR 1.23, 95% CI 1.14–1.32), and recessive (OR 1.25, 95% CI 1.12–1.41). For psoriatic arthritis specifically, a Serbian case-control study⁹⁹ Serbian case-control study
Popadic et al., International Journal of Immunogenetics, 2014 found the G allele frequency was substantially higher in PsA patients vs. controls (48.1% vs. 30.8%), with carriage of any G allele conferring a striking OR of 3.31 (95% CI 1.29–8.70, P=0.009).

For Crohn's disease, a meta-analysis of 18 case-control studies (6,846 cases, 9,056 controls)¹⁰¹⁰ meta-analysis of 18 case-control studies (6,846 cases, 9,056 controls)
Du et al., Scientific Reports, 2015 found the rs2201841 risk allele associated with CD risk with OR 1.37–1.41 in Caucasian and African subjects, with no significant effect in Asians. Notably, the combined risk of rs2201841 plus positive CARD15 (NOD2) status reached OR 9.15 — a striking gene-gene interaction in Crohn's disease pathogenesis.

For ankylosing spondylitis, a meta-analysis of 25 studies (8,431 AS cases, 8,972 controls)¹¹¹¹ meta-analysis of 25 studies (8,431 AS cases, 8,972 controls)
2018 confirmed that the rs2201841 minor allele frequency was significantly higher in AS cases vs. controls (P=0.010), with significant association in Europeans but not in East Asian populations — consistent with the overall higher G allele frequency (~71%) in East Asians, which may reduce statistical power for detecting risk associated with a common allele.

A signal of broader metabolic impact also emerged: the GG genotype was associated with type 2 diabetes comorbidity¹²¹² GG genotype was associated with type 2 diabetes comorbidity
Cubero et al., Journal of Dermatological Science, 2014 in psoriasis patients (OR 2.69, 95% CI 1.09–6.66), adding metabolic risk context consistent with the broader inflammatory burden in GG carriers.

Practical Implications

The principal clinical relevance of rs2201841 is as a susceptibility marker that anchors to the IL-23/Th17 inflammatory axis¹³¹³ IL-23/Th17 inflammatory axis
The IL-23 → Th17 → IL-17 pathway is one of the most druggable axes in modern rheumatology and dermatology, with multiple approved biologics targeting different nodes — the same axis targeted by all currently approved IL-17 inhibitors (secukinumab, ixekizumab, brodalumab) and IL-23 inhibitors (ustekinumab, risankizumab, guselkumab, tildrakizumab). Carrying the GG genotype does not predict differential response to these agents — no established pharmacogenomic guideline ties rs2201841 to biologic dosing or selection — but it does identify individuals with heightened baseline IL-23 pathway activity who may benefit from proactive screening for psoriatic disease and IBD.

The overlapping genetic architecture means that GG carriers should be aware of the full spectrum of conditions sharing this axis: psoriasis, psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease. Symptoms of one should prompt evaluation for the others, and rheumatology or gastroenterology referral may be warranted when musculoskeletal or gastrointestinal symptoms emerge alongside skin findings.

Interactions

rs2201841 operates in the same biological corridor as rs33980500 (TRAF3IP2/Act1 D10N), which encodes the signaling adaptor directly downstream of IL17RA — the receptor that receives IL-17A signals produced by Th17 cells activated through IL-23R. Carrying G alleles at rs2201841 amplifies IL-23-driven Th17 expansion; the Act1 D10N variant then shapes how those Th17-derived IL-17 signals are transduced. The two SNPs tag different nodes in the same IL-23 → Th17 → IL-17 → Act1 cascade and may compound risk for psoriatic disease when present together.

rs11209026 (R381Q, Arg381Gln) in the same IL23R gene is the key protective counterpart: the Q381 allele reduces receptor surface expression and IL-23 signaling, protecting against psoriasis, Crohn's, and AS. An individual homozygous for rs2201841 G who also carries the protective Q381 allele at rs11209026 may have partially offset risk — these two IL23R variants capture different aspects of receptor biology at the same locus.

The C3 gene encodes complement component 3, the central protein of the complement cascade, an ancient immune surveillance system that clears pathogens and cellular debris. The R102G variant (rs2230199)¹¹ R102G variant (rs2230199)
also known as the C3F/C3S polymorphism substitutes arginine for glycine at position 102, creating the "fast" (C3F, glycine) electrophoretic variant versus the common "slow" (C3S, arginine) form. This amino acid change has functional consequences for complement regulation and is strongly associated with age-related macular degeneration²² strongly associated with age-related macular degeneration
Yates et al. NEJM 2007 (AMD), the leading cause of vision loss in the elderly.

The Mechanism

C3 sits at the convergence point of all three complement activation pathways. When activated, C3 is cleaved into C3a (an inflammatory signaling molecule) and C3b (which tags surfaces for destruction). The R102G substitution occurs in the MG1 domain of C3, altering a critical salt bridge (Arg102-Glu1032)³³ altering a critical salt bridge (Arg102-Glu1032)
crystal structure studies that stabilizes the protein's inactive form. The glycine variant (C allele) creates a more reactive C3 protein with enhanced complement activation and reduced regulation by complement factor H.

In the eye, dysregulated complement activation drives drusen formation—yellow deposits of lipids, proteins, and complement fragments that accumulate between the retinal pigment epithelium and Bruch's membrane. Drusen contain C3 and C3 activation fragments⁴⁴ Drusen contain C3 and C3 activation fragments
Johnson et al. 2001, marking sites of chronic inflammation. The G102 variant amplifies this inflammatory cascade, accelerating drusen growth and progression to advanced AMD with vision loss.

The Evidence

The association between C3 R102G and AMD is robust and replicated⁵⁵ association between C3 R102G and AMD is robust and replicated
systematic review, Thakkinstian et al. 2011. A meta-analysis of 16 studies found heterozygotes (CG) have 1.44 times higher AMD risk (95% CI 1.33-1.56), while homozygotes (CC) have 1.88 times higher risk (95% CI 1.59-2.23) compared to GG genotypes. The largest GWAS to date⁶⁶ largest GWAS to date
Fritsche et al. Nature Genetics 2013 independently confirmed the C3 locus as one of 19 AMD-associated loci in over 17,100 cases and 60,000 controls of European and Asian ancestry.

The variant shows strong ethnic variation⁷⁷ strong ethnic variation
Yanagisawa et al. 2011: the C risk allele reaches 20% frequency in Europeans but is essentially absent (<1%) in Japanese and Chinese populations, where different C3 variants drive AMD susceptibility. In European-ancestry populations, R102G explains approximately 17-22% of AMD attributable risk, independent of other major risk genes like CFH Y402H.

Functional studies demonstrate that the C3F and C3S allotypes exhibit similar binding to complement receptors CR1, CR2, and CR3⁸⁸ similar binding to complement receptors CR1, CR2, and CR3
Bartók and Walport 1995 but differ in complement activation efficiency, and the R102G substitution affects C3b protein stability in physiological salt concentrations⁹⁹ affects C3b protein stability in physiological salt concentrations
Perkins et al. 2015. The variant has also been linked to other complement-mediated diseases including IgA nephropathy and membranoproliferative glomerulonephritis type II, underscoring its functional impact on immune regulation.

Practical Implications

If you carry one or two C alleles, you face moderately to significantly increased risk for AMD, particularly after age 60. The disease manifests as blurred or distorted central vision, difficulty reading, and dark or empty areas in the visual field. Early detection through regular dilated eye exams is critical—progression can be slowed¹⁰¹⁰ progression can be slowed
AREDS2 study with nutritional supplementation (zinc, copper, vitamins C and E, lutein, zeaxanthin) for intermediate or advanced AMD in one eye.

Smoking dramatically amplifies AMD risk across all genotypes and should be avoided entirely. Some evidence suggests omega-3 fatty acids may be protective, though results are mixed. For advanced wet AMD, anti-VEGF injections can preserve vision. Emerging complement-targeted therapies (C3 inhibitors like pegcetacoplan) show promise for geographic atrophy, though results are complex.

The complementopathy extends beyond the eye: carriers of the C3F allele show accelerated CKD progression specifically in IgA nephropathy¹¹¹¹ carriers of the C3F allele show accelerated CKD progression specifically in IgA nephropathy
Mihai et al. 2020, as the complement system also regulates renal inflammation. Consider discussing family history and early screening with an ophthalmologist, especially if you have multiple AMD risk factors.

Interactions

C3 R102G interacts with other complement pathway variants to modify AMD risk. The most important interaction is with CFH Y402H (rs1061170), the strongest genetic risk factor for AMD. Individuals carrying risk alleles at both loci face compounded risk—the two genes operate in the same biological pathway but represent distinct mechanistic failures (CFH regulates complement, while C3 executes it). Studies show no statistical interaction between the two variants, meaning their effects are independent and additive.

C3 R102G is in strong linkage disequilibrium with another C3 variant, P314L (rs1047286), making it difficult to separate their individual effects. However, conditional analyses suggest R102G is the primary functional variant. Other complement genes (CFB, CFI, C2) also influence AMD risk but show no evidence of statistical interaction with C3 R102G.

Environmental factors modify genetic risk: smoking has the strongest effect, with smokers who carry the CC genotype facing dramatically elevated AMD risk. High dietary intake of omega-3 fatty acids¹²¹² High dietary intake of omega-3 fatty acids
SanGiovanni et al. 2008 may partially offset genetic risk, though this remains under investigation. The interplay between complement genetics and lipid metabolism in drusen formation suggests dietary fats influence disease expression in genetically susceptible individuals.

Every cell in your body carries a molecular self-destruct switch. When that switch is working correctly, damaged or pre-cancerous cells receive a signal through the Fas death receptor¹¹ Fas death receptor
Fas (also called CD95 or APO-1) is a cell-surface receptor that, when bound by Fas ligand on immune cells, triggers a caspase cascade leading to programmed cell death (apoptosis). This is one of the primary mechanisms immune cells use to eliminate virus-infected or pre-malignant cells and quietly eliminate themselves. PTPN13 — also known as FAP-1 (Fas-Associated Phosphatase 1) — encodes a large protein tyrosine phosphatase that sits at this critical junction, regulating how sensitively cells respond to the Fas apoptosis signal. The rs2230600 variant (c.4566A>G, I1522M) is a common missense change in PTPN13's catalytic region that has been associated with elevated risk for multiple squamous cell carcinomas in two independent case-control studies.

The Mechanism

PTPN13 is one of the largest protein tyrosine phosphatases in the human genome — a 2,466-amino-acid protein containing five PDZ domains, a FERM domain, and a C-terminal phosphatase catalytic domain. It acts as a negative regulator of the Fas apoptosis pathway by dephosphorylating phospho-tyrosine 275 on the Fas receptor²² dephosphorylating phospho-tyrosine 275 on the Fas receptor
Tyrosine phosphorylation of Fas at Y275 is required for downstream caspase activation; FAP-1 removes this phosphate group, reducing Fas signaling capacity and the cell's willingness to undergo apoptosis. When PTPN13 activity is reduced or altered, Fas signaling is partially restored and cells become more responsive to immune-mediated elimination.

The p.Ile1522Met substitution changes an isoleucine to a methionine at position 1522 within the large N-terminal regulatory region of the protein. While the precise structural consequence has not been fully characterized at atomic resolution, position 1522 lies within a region that influences protein folding and intermolecular interactions. The variant is thought to subtly alter protein conformation or PDZ domain-mediated interactions, potentially reducing the efficiency with which FAP-1 dephosphorylates Fas and its other substrates including IκBα (a regulator of NF-κB) and STAT1. Separately, elevated FAP-1 expression in cancer cells has been shown to activate NF-κB³³ NF-κB
Nuclear factor kappa B — a master transcription factor regulating immune responses, inflammation, and cell survival; its constitutive activation in cancer cells promotes resistance to apoptosis and chemotherapy, creating a dual apoptosis resistance mechanism relevant to the I1522M context.

A 2026 study in Cell Research added an important new dimension: PTPN13 dephosphorylates STAT1, suppressing MHC class I antigen presentation and reducing CD8+ T cell infiltration into tumors. This immune evasion pathway, operating downstream of APC loss in colorectal cancer, positions PTPN13 as a regulator of the tumor immune microenvironment — not just an intracellular apoptosis gatekeeper.

The Evidence

The primary genetic evidence for rs2230600 comes from a US case-control study of head and neck squamous cell carcinoma⁴⁴ US case-control study of head and neck squamous cell carcinoma
Niu et al., Carcinogenesis 2009; 1,069 SCCHN patients and 1,102 cancer-free non-Hispanic white controls that found the GG genotype carried an odds ratio of 1.89 (95% CI 1.27–2.79) compared to AA. The risk was most pronounced in younger patients (≤57 years), males, never-smokers, current alcohol drinkers, and those with pharyngeal cancers — subgroups where environmental exposure and HPV-independent pathways may matter more, making the genetic contribution proportionally larger. This study also examined two other PTPN13 coding variants (F1356L at rs10033029 and Y2081D at rs989902), of which Y2081D showed a modest independent signal (GT genotype OR 1.26).

A Japanese study⁵⁵ Japanese study
Mita et al., J Cancer Res Clin Oncol 2010; 569 cancer patients and 819 controls across colorectal, lung, head/neck, and esophageal cancers extended these findings to a broader cancer spectrum. When I1522M and Y2081D were analyzed as a combination genotype, odds ratios for specific cancer subtypes reached 3.36–13.75, suggesting that PTPN13 variants may act additively across multiple tumor types — though the small sample sizes for individual cancer subtypes introduce considerable uncertainty around these estimates.

At the somatic level, PTPN13 is mutated in approximately 26% of colorectal cancers alongside five other tyrosine phosphatase genes, with frameshift and nonsense mutations predominating⁶⁶ frameshift and nonsense mutations predominating
Wang et al., Science 2004; the study showed wild-type PTPN13 expression suppresses cancer cell proliferation while mutant forms do not. This somatic evidence supports PTPN13 as a bona fide tumor suppressor, contextualizing the germline I1522M variant as a partial, constitutional impairment of the same protective mechanism.

The overall evidence level for I1522M specifically is moderate: two independent case-control studies with consistent directionality, plausible functional mechanism, but no GWAS Catalog entries and no clinical guideline recognition.

Practical Implications

For GG homozygotes, the roughly twofold increased odds ratio for SCCHN is clinically meaningful for individuals with additional risk factors — alcohol use, tobacco, or occupational carcinogen exposures — since these exposures interact with the underlying apoptotic regulation that PTPN13 governs. The cancer types most strongly linked to this variant are squamous cell carcinomas of the head, neck, and upper aerodigestive tract. Awareness of oral cavity symptoms and consistent dental/ENT surveillance is appropriate. For AG heterozygotes, the intermediate risk warrants attention without the same urgency.

Interactions

The PTPN13 variant rs989902 (Y2081D) shows an independent and potentially additive effect with rs2230600 (I1522M) in Japanese cancer cohorts. Individuals carrying risk alleles at both positions may be in a higher-risk category than either variant alone predicts. The rs2230600 G allele may also interact with somatic loss of the second PTPN13 allele (loss of heterozygosity is common in colorectal tumors), making it a potential contributor to acquired cancer progression rather than just inherited risk.

The follicle-stimulating hormone receptor gene (FSHR) harbors three well-studied variants that influence reproductive outcomes: the two missense variants rs6165 (Ala307Thr) and rs6166 (Asn680Ser) in the coding region, and this intronic variant rs2268361, located 5,590 bases upstream of exon 7 within intron 6 NM_000145.4:c.669-5590G>T¹¹ NM_000145.4:c.669-5590G>T
Transcriptional notation on the minus strand; the variant is C>T on the plus (genome file) strand. While it does not change the FSHR protein sequence, rs2268361 was independently identified as a PCOS risk locus in genome-wide association studies of Han Chinese women and subsequently replicated across European and other ancestries. The C allele tags a haplotype associated with elevated basal FSH and increased PCOS susceptibility; the T allele is protective and associated with normal FSH levels.

The Mechanism

As an intronic variant, rs2268361 does not alter any amino acid in the FSH receptor protein. Its functional effect is presumed to be regulatory — affecting how much FSHR mRNA is produced or how it is processed²² regulatory — affecting how much FSHR mRNA is produced or how it is processed
Intronic variants can act as splicing regulators, transcription factor binding sites, or LD tags for nearby functional elements. The precise molecular mechanism has not been established in published functional studies as of 2026. The most parsimonious interpretation is that rs2268361 tags a regulatory haplotype that subtly reduces FSHR expression or alters splicing efficiency in granulosa cells, leading downstream to compensatory pituitary FSH secretion and modestly altered FSH receptor signaling in the ovary.

Importantly, this locus is distinct from the rs6165/rs6166 haplotype. While rs6165 and rs6166 are in near-complete linkage disequilibrium with each other (r²>0.80), rs2268361 represents an independent signal at the FSHR locus³³ an independent signal at the FSHR locus
The Shi et al. 2012 GWAS specifically identified this as a second independent signal at 2p16.3, separate from the coding-variant haplotype. This means rs2268361 may carry additional predictive information even in individuals already genotyped for rs6165 and rs6166.

The Evidence

The clearest functional evidence comes from a cross-ethnic replication study of 2,718 women⁴⁴ cross-ethnic replication study of 2,718 women
Saxena et al., Human Reproduction 2015 that tested 11 Han Chinese GWAS PCOS variants in European ancestry cohorts (Boston discovery: 485 PCOS cases, 407 controls; Greece: 884 cases, 311 controls; Boston EMR: 350 cases, 1,258 controls). Of the 11 variants tested, rs2268361-T was the clearest replicating signal: OR 0.84 (95% CI 0.76–0.93, P=0.002) for PCOS protection, and a significant reduction in FSH concentrations in T carriers (beta=-0.15 ± 0.05, P=0.0029 in standardized units). The FSH-lowering effect of the T allele aligns with the PCOS-protective effect: less FSH stimulation (or more efficient receptor response) reduces the hormonal milieu that promotes PCOS pathophysiology.

A large meta-analysis of 47 case-control studies⁵⁵ large meta-analysis of 47 case-control studies
Sharma et al., Metabolic Syndrome and Related Disorders 2023 covering 10,584 PCOS cases and 16,150 controls confirmed the protective direction of effect: OR 0.84 (95% CI 0.78–0.89) for the T allele (or equivalently, the C allele confers risk at OR ~1.19–1.28). This consistency across 47 studies spanning multiple ethnicities places the association on firm epidemiological ground, though the functional mechanism remains incompletely characterized.

Not all individual studies replicate the finding. A Chinese case-control study of 400 PCOS women and 480 controls⁶⁶ Chinese case-control study of 400 PCOS women and 480 controls
Zhang et al., Journal of Assisted Reproduction and Genetics 2021 did not find a significant association for rs2268361 in isolation, though rs6166 (the coding variant) showed significant effects. This heterogeneity across populations is expected for an intronic regulatory variant whose effect may depend on local linkage patterns and population history.

A Saudi Arabian case-control study⁷⁷ Saudi Arabian case-control study
Alharbi et al., BMC Endocrine Disorders 2019 observed that homozygous TT genotype at rs2268361 was associated with normal AMH levels among non-PCOS women, suggesting the TT genotype is associated with a preserved ovarian reserve signal in healthy controls. While this was a small study (95 PCOS cases, 94 controls), it aligns with the biological model of T allele maintaining appropriate FSH-receptor axis sensitivity.

Epistatic studies add additional nuance. A Colombian PCOS cohort study⁸⁸ A Colombian PCOS cohort study
Bernal-Hernández et al., Genes 2024 identified rs2268361 as part of the best-fit three-locus synergistic interaction model (P<0.0001), paired with two other FSHR/TOX3 variants. This suggests that the independent additive effect of rs2268361 is amplified in specific genetic backgrounds.

Practical Implications

For most individuals carrying one or two C alleles, the practical implications are subtle rather than deterministic. The variant modulates PCOS susceptibility at a population level (shifting OR by ~19%) but does not define individual outcome. Its main clinical relevance lies in two areas:

Basal FSH interpretation: The C allele tracks with modestly elevated FSH levels even in non-PCOS women. Women with CC or CT genotypes who have elevated day-3 FSH should have this contextualized alongside AMH — the FSHR rs2268361 C allele may contribute a small upward push to basal FSH independent of ovarian reserve.

PCOS context: In women already diagnosed with or suspected of PCOS, carrying the CC genotype adds to the overall genetic burden at the FSHR locus. Combined with the rs6165/rs6166 haplotype status, a full FSHR genotype picture (three variants) gives the most complete assessment of FSHR-axis function.

Interactions

rs6166 (FSHR Asn680Ser) and rs6165 (FSHR Ala307Thr): rs2268361 represents an independent genetic signal at the FSHR locus. Unlike the near-complete LD between rs6165 and rs6166 (r²>0.80), rs2268361 is not captured by the coding-variant haplotype. Individuals heterozygous at rs2268361 (CT) who are also homozygous for the coding-variant risk haplotype (CC at rs6165, GG at rs6166) carry risk signals from two independent FSHR mechanisms — the regulatory/intronic effect (rs2268361) and the protein-level sensitivity changes (rs6165/rs6166). The combined FSHR genetic burden has not been formally quantified in a single integrated model.

rs1394205 (FSHR promoter, -29G>A): The FSHR promoter variant rs1394205 also operates at the expression level rather than protein sequence. The relationship between rs2268361 and rs1394205 LD is not well characterized in published literature; they may operate through different regulatory elements on the same gene.

Zinc is not simply a passive micronutrient. It functions as a catalytic cofactor in more than 300 enzymes, a structural component of over 1,000 zinc-finger proteins, and a dynamic signaling ion — shifting rapidly between cellular compartments to coordinate immune responses, DNA repair, insulin crystallization, and antioxidant defense. The cell's ability to manage these zinc fluxes depends critically on a family of zinc transporters¹¹ zinc transporters
SLC30A (ZnT) family: 10 members that export zinc from the cytoplasm into organelles or across the plasma membrane to the extracellular space, of which ZnT1 encoded by SLC30A1 is the most ubiquitously expressed and the only one localized exclusively to the plasma membrane.

rs2278651 is an intronic variant at position 211,577,718 on chromosome 1 (GRCh38), located 273 nucleotides downstream of exon 4 in the SLC30A1 transcript (c.622+273T>G on the coding strand; A>G on the plus strand). The variant is not in ClinVar and carries no published phenotypic association in the GWAS Catalog, placing it in the emerging evidence tier. The minor A allele (the GRCh38 reference) occurs at roughly 38% globally and up to 45% in Europeans — common enough that the heterozygote genotype (AG) is the single most frequent genotype in most populations (~47%). The biological plausibility for functional impact rests on the well-characterized biology of ZnT1 in tissues where zinc balance matters most.

The Mechanism

ZnT1 is the primary route by which cytosolic zinc exits the cell across the plasma membrane. When ZnT1 function or expression is reduced, free zinc accumulates in the cytosol. This accumulation triggers compensatory upregulation of metallothioneins²² metallothioneins
Cysteine-rich zinc-binding proteins that sequester free zinc; act as a cytosolic zinc buffer but also suppress NF-κB and nitric oxide signaling when overloaded, which paradoxically blunts immune signaling and antioxidant responses rather than protecting the cell.

Because rs2278651 is intronic, it does not alter the ZnT1 protein sequence directly. Intronic variants can, however, influence gene expression through splicing regulatory elements, transcription factor binding sites embedded in deep intronic sequence, or chromatin accessibility changes. None of these mechanisms have been experimentally validated for rs2278651 specifically — the functional link, if any, remains mechanistically uncharacterized.

SLC30A1 expression is tightly regulated by zinc availability: ZnT1 protein increases when intracellular zinc rises (protecting against toxicity) and decreases when zinc is depleted (conserving intracellular zinc). A variant that disrupts this feedback-responsive expression could therefore blunt the cell's dynamic range for zinc management without producing a fixed change detectable in standard blood work.

The Evidence

The most informative functional data for SLC30A1 in human-relevant contexts comes from conditional knockout models and immune cell studies rather than from population genetics:

Cao et al. 2024 (eLife)³³ Cao et al. 2024 (eLife)
The zinc transporter Slc30a1 (ZnT1) in macrophages plays a protective role against attenuated Salmonella. eLife demonstrated that macrophage-specific deletion of SLC30A1 in mice impaired intracellular bacterial killing, reduced NF-κB activation, and decreased inducible nitric oxide synthase (iNOS) production — the primary effector mechanism macrophages use against intracellular pathogens. The defect was attributable to aberrant intracellular zinc accumulation suppressing immune signaling, not to insufficient zinc delivery to the pathogen.

Lehmann et al. 2021 (J Leukocyte Biology)⁴⁴ Lehmann et al. 2021 (J Leukocyte Biology)
LPS-inducible SLC30A1 drives human macrophage-mediated zinc toxicity against intracellular E. coli. J Leukocyte Biol showed that in primary human macrophages, SLC30A1 is constitutively expressed but strongly upregulated by LPS stimulation. ZnT1-mediated zinc flux contributes to zinc-mediated bactericidal activity — a mechanism that depends on regulated, not constitutive, transporter expression.

Jenkitkasemwong et al. 2009 (J Nutr)⁵⁵ Jenkitkasemwong et al. 2009 (J Nutr)
Zinc transporters ZnT1, Zip8, and Zip10 in mouse red blood cells are differentially regulated during erythroid development and by dietary zinc deficiency. J Nutr showed that ZnT1 protein increases 2.3-fold during EPO-driven erythroid differentiation and decreases significantly in zinc-deficient mice, coupling ZnT1 expression to both erythropoietic demand and dietary zinc supply.

Nanba et al. 2023 (Nature Genetics)⁶⁶ Nanba et al. 2023 (Nature Genetics)
Somatic SLC30A1 mutations altering zinc transporter ZnT1 cause aldosterone-producing adenomas and primary aldosteronism. Nat Genet characterized in-frame deletions near the SLC30A1 zinc-binding domain that convert ZnT1 into an aberrant sodium channel, confirming that ZnT1 ion selectivity at transmembrane domain II is functionally essential. These are somatic tumor mutations, not germline variants, but they establish the mechanistic sensitivity of this transporter to structural disruption.

Practical Actions

For individuals carrying one or two A alleles at rs2278651, the most directly actionable step is ensuring dietary zinc is adequate and optimally absorbed. ZnT1 expression responds to zinc supply: when intake is sufficient, cells can up-regulate ZnT1 to clear excess cytosolic zinc efficiently. When dietary zinc is borderline, any intrinsic baseline reduction in ZnT1 expression may be compounded by reduced substrate availability.

Dietary sources with high zinc bioavailability include oysters (highest per serving), red meat, shellfish, and dairy. Plant-based sources contain zinc but also phytates that inhibit absorption — vegans and vegetarians consistently show lower serum zinc than omnivores on equivalent intakes. Soaking and fermenting legumes reduces phytate content and improves zinc bioavailability.

Monitoring serum zinc is reasonable for AA homozygotes, though a single serum zinc measurement has limitations (it reflects circulating rather than intracellular zinc, and normal reference ranges do not capture functional adequacy at the cellular level).

Interactions

SLC30A1 is one of ten SLC30A family members. rs2278651 exists in the same gene as the other SLC30A1 candidate variant rs11277 (3′ UTR). If both variants are present, their combined effect on ZnT1 expression is unknown but may be additive given they act on the same gene through potentially independent regulatory elements.

ZnT8 (SLC30A8), encoded by a separate gene, transports zinc into insulin secretory granules in pancreatic beta cells. Common SLC30A8 variants (rs13266634) affecting insulin-zinc crystallization interact with dietary zinc status in ways that parallel SLC30A1's role in cellular zinc export. Individuals carrying risk alleles at both loci may benefit most from optimizing zinc bioavailability.

Interferon Regulatory Factor 5 (IRF5) is a master transcription factor controlling the production of type I interferons (IFN-α and IFN-β) and pro-inflammatory cytokines including TNF-α, IL-6, and IL-12. The rs2280714 variant sits approximately 5 kb downstream of the IRF5 coding sequence in the 3' regulatory region. Although it is not the primary causal variant at this position, it is a reliable tag for the IRF5 risk haplotype¹¹ risk haplotype
A set of nearby variants that travel together through generations as a block; rs2280714-T marks one of three independent functional blocks in the IRF5 autoimmune risk haplotype and independently correlates with elevated IRF5 mRNA levels across multiple ancestral populations. Individuals carrying the T allele are more likely to have an immune system primed toward higher baseline interferon output — the same molecular signature underlying lupus, systemic sclerosis, and Sjögren syndrome susceptibility.

The Mechanism

The rs2280714 variant lies within the 3' regulatory region that controls IRF5 mRNA stability and polyadenylation site selection. Functional studies in lymphoblastoid cell lines from European, Han Chinese/Japanese, and Yoruba Nigerian individuals showed that the major T allele of rs2280714 correlates with a relative IRF5 expression ratio of 1.7-fold in Europeans²² major T allele of rs2280714 correlates with a relative IRF5 expression ratio of 1.7-fold in Europeans
Bonferroni-corrected p<0.0001 in CEU; p=0.001 in CHB+JPT; p=0.004 in YRI — consistent across three ancestral populations compared to individuals carrying the C allele, a pattern that was consistent across all three ancestral groups tested.

The closely linked variant rs10954213 (D'=1, r²=0.79 with rs2280714) is the primary functional element: its A allele creates a canonical AAUAAA polyadenylation signal that is disrupted by the G allele, causing mRNA cleavage and polyadenylation to shift to a more distal site. The shorter 3'-UTR transcript produced when the functional polyA site is used is more stable and more abundant³³ more stable and more abundant
The 3'-UTR length affects miRNA binding site accessibility and mRNA half-life; the shorter isoform escapes miRNA-mediated degradation and accumulates to higher levels. Because rs2280714-T tracks so closely with rs10954213-A in most haplotype blocks, the two variants show essentially interchangeable associations in most population studies. The key point is that carrying rs2280714-T means you very likely also carry the functional polyadenylation variant that elevates IRF5 expression.

The combined haplotype rs2004640-T / rs10954213-A / rs2280714-T produces a "double-hit" to IRF5 regulation: rs2004640 enables expression of an alternative exon 1B that generates more active IRF5 isoforms, while the polyadenylation variant (tagged by rs2280714) stabilizes those transcripts. Together they sustain higher baseline and inducible IRF5 activity — a lower immune threshold for triggering and maintaining the type I interferon cascade⁴⁴ lower immune threshold for triggering and maintaining the type I interferon cascade
The interferon cascade is normally self-limiting; these variants shift the setpoint so that the same immune stimulus produces a larger and more sustained response.

The Evidence

The clearest evidence comes from the UK SLE family study which found over-transmission of the rs2280714 T allele⁵⁵ found over-transmission of the rs2280714 T allele
GH-TDT P=0.007; FBAT P=0.015; transmission ratio 1:1.35 favoring T in affected offspring. The combined TAT haplotype (rs2004640-T / rs10954213-A / rs2280714-T) showed a dose-dependent relationship with IRF5 mRNA expression, confirming that allele count at this locus tracks linearly with output.

A Korean SLE replication study found that while rs2280714-T alone was not independently associated with SLE⁶⁶ found that while rs2280714-T alone was not independently associated with SLE
T allele frequency 0.395 in cases vs 0.402 in controls, OR=0.97, P=0.70, the two-marker haplotype rs2004640-T / rs2280714-T showed strong association (cases 0.380, controls 0.311, OR=1.36, P=9.64×10⁻⁵). Pooled across all ancestries, this haplotype reached P=2.11×10⁻¹⁶, establishing it as one of the most replicated autoimmune susceptibility signals in genetics. This pattern — weak independent signal but strong haplotype effect — is characteristic of secondary tag SNPs in tight LD with a functional variant, and is consistent with rs2280714's role as a proxy for rs10954213.

In systemic sclerosis, a Japanese study of 283 patients found that rs2280714 showed the strongest association among three IRF5 SNPs tested⁷⁷ the strongest association among three IRF5 SNPs tested
OR=1.42 (95% CI 1.15–1.75), P=0.0012, with preferential enrichment in diffuse cutaneous SSc and anti-topoisomerase I antibody-positive subsets — the disease subtypes with the most aggressive fibrotic and inflammatory features. This points to IRF5 as a driver of not just autoimmune susceptibility but also disease severity in SSc.

IRF5 mRNA expression has also been found elevated in NMOSD patients compared to controls in some cohorts, suggesting the interferon-amplifying haplotype may contribute to a broader class of autoimmune neuroinflammatory conditions. However, population-specific effects have been observed, and the rs2280714 variant alone shows inconsistent independent associations in NMOSD studies.

For rheumatoid arthritis, the evidence for rs2280714 as an independent risk factor is weak — the variant shows no significant association with RA across European cohorts — consistent with its role as a secondary tag rather than a primary functional variant for RA-specific disease pathways.

Practical Implications

Carrying the T allele, particularly one or two copies, means your IRF5 expression is likely modestly elevated at baseline compared to CC individuals. This does not predetermine autoimmune disease — the majority of T allele carriers remain healthy — but it means your type I interferon pathway operates closer to the threshold needed for chronic activation. Awareness is the main actionable output: recognizing early signs of IRF5-related autoimmune conditions enables earlier evaluation and intervention, which substantially improves long-term outcomes.

For most people with the CT genotype, no specialist referral is needed without symptoms. However, if other IRF5 risk variants (rs2004640-T or rs10488631-C) are also present, the combined haplotype risk is substantially higher, and proactive monitoring becomes more appropriate (those compound effects are captured by the haplotype analysis across all three IRF5 SNPs).

Interactions

The rs2280714-T allele is biologically meaningful primarily when co-inherited with rs2004640-T on the same chromosome (in cis), forming the risk haplotype. The combined haplotype (rs2004640-T / rs2280714-T) represents both altered splicing AND elevated transcript stability — a mechanistic synergy captured by the haplotype's pooled association of P=2.11×10⁻¹⁶ for SLE, far exceeding either variant's independent contribution.

rs2280714 is also part of the broader three-block IRF5 haplotype system alongside rs10488631 (3' downstream regulatory) and rs4728142 (promoter CGGGG indel). Individuals carrying risk alleles across all three blocks have the highest IRF5 expression and autoimmune risk. Additionally, the IRF5 risk haplotype interacts additively with STAT4 rs7574865, which amplifies cellular responsiveness to the interferons IRF5 drives — individuals with risk alleles at both loci can reach substantially amplified autoimmune risk up to OR=6.78 with five combined risk alleles in Sjögren's syndrome⁸⁸ up to OR=6.78 with five combined risk alleles in Sjögren's syndrome
Nordmark et al. Genes & Immunity 2009.